The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. UCSF’s long tradition of excellence in cancer research includes the Nobel Prize-winning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes. Their work opened new doors for exploring genetic abnormalities that cause cancer and formed the basis for some of the most important cancer research happening today. In addition to the HDFCCC’s robust breast cancer research and treatment program, UCSF is home to the Center for BRCA Research, one of only two such centers in the US. Its mission is to provide a central resource for families with BRCA and other mutations to receive personalized care and planning for their long-term health and well-being. This is our opportunity to rethink how we treat and manage hereditary cancers.
For more information please visit www.cancer.ucsf.edu

At Endomag, we believe everyone deserves a better standard of cancer care. With many of the world’s best physicians and cancer hospitals using our technologies for breast cancer surgery, we’re helping to prevent avoidable operations and sparing women from potential complications. When surgery is necessary, we’ve improved outcomes for tens of thousands, through more precise and less invasive surgery. Most importantly, our techniques are giving patients greater access to the best standards of treatment worldwide.
With the Sentimag® probe, physicians can perform both advanced lesion localization with the Magseed® marker and sentinel node biopsies with the Magtrace® lymphatic tracer.
For more information please visit www.endomagnetics.com

Stryker is one of the world’s leading medical technology companies. We offer products and services that help improve patient and hospital outcomes. Stryker’s visualization platform enables surgeons to distinguish anatomy across minimally invasive and open procedures. Our history of innovation in advanced imaging is driven by the desire to allow you to see and do more. SPY Portable Handheld Imager (SPY-PHI) allows surgeons to visualize blood flow in vessels and related tissue perfusion during plastic, microsurgical, reconstructive and gastrointestinal procedures. SPY-PHI is a unique and versatile fluorescence imaging system that provides clinicians with a convenient solution for perfusion assessment.
For more information please visit www.stryker.com

Genomic Health, Inc. is the world’s leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for over 1 million cancer patients worldwide. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland.
For more information please visit www.genomichealth.com

PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Patient Focused: We realize that every sample that comes through our laboratory has a patient behind it and it is our job to ensure that we handle each sample with care and provide results back to the patient and physician in a timely manner. PreludeDx exists to take care of the needs of our patients.
Quality First: We will put quality systems and processes first and foremost as we provide the highest quality results to our patients and physicians.
Driving Innovation: PreludeDx will strive to find new innovative tools and processes that assist patients and physicians for the better management of cancer.
DCISionRT is the only test capable of predicting an individual patient’s benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.
For more information please visit www.preludedx.com

Founded more than 40 years ago, Genentech, a member of the Roche Group, is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. Our medicines, along with companion diagnostic tests, have substantially improved outcomes for HER2-positive breast cancer. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including triple-negative and hormone receptor-positive.
For more information please visit www.gene.com

Cianna Medical, a wholly-owned subsidiary of Merit Medical, is the world leader in wire-free breast localization and has been focused on breast conservation for over 11 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical developed the world’s first non-radioactive, wire-free radar breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT® and SAVI® Brachy technologies are FDA cleared and address unmet needs in the delivery of radiation therapy, tumor and soft tissue localization and surgical guidance
For more information please visit www.ciannamedical.com

At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging health care issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
As a leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.
We are passionate about what we do and the impact we have on patients and societies.
We are Novartis, and we are reimagining medicine.
For more information please visit www.novartis.com

Hologic is an innovative medical technology company primarily focused on improving women’s health and well-being. By activating what we call The Science of Sure, we enable healthier lives with clinical superiority that delivers life-changing diagnostic, detection, surgical and medical aesthetic products rooted in science and driven by technology. Hologic: The Science of Sure in action.
For more information please visit www.hologic.com

Agendia is a leading precision oncology company that develops genomic tests to help support physicians faced with complex treatment decisions for women with breast cancer. MammaPrint®, the 70-gene breast cancer recurrence assay, developed for use by physicians as a prognostic marker, is the only FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective outcome data and is included in many national and international guidelines. BluePrint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer.
For more information please visit www.agendia.com

Mediknox is a national distributor of the most advanced light therapy devices in the market today.
Researchers found to be beneficial for different medical conditions, such:

• promotes wound healing and tissue repair
• improves hair growth in people with androgenic alopecia
• help for the short-term treatment of carpal tunnel syndrome
• stimulates healing of slow-healing wounds, like diabetic foot ulcers
• reduces psoriasis lesions
• aids with short-term relief of pain and morning stiffness in people with rheumatoid arthritis
• reduces some of the side effects of cancer treatments, including oral mucositis
• improves skin complexion and builds collagen to diminish wrinkles
• helps to mend sun damage
• prevents recurring cold sores from herpes simplex virus infections
• improves the health of joints in people with degenerative osteoarthritis of the knee
• helps diminish scars
• relieves pain and inflammation in people with pain in the Achilles tendon

We work with the most advanced medical devices, and simplify professional medical technology for home use.
This Technology is clinically proven, and FDA cleared medical devices, and currently carried, used and sold by medical professionals, including those within this field.
For more information please visit www.mediknox.com

OncoRes Medical Pty Ltd (OncoRes) is a medical device company focussed on the development of intraoperative imaging technology, to provide cancer surgeons with real-time assessment of tissue microstructure. The first indication we are focussed on is breast; specifically a reduction in the re-excision rate for breast conserving surgery.
Our technology utilises a novel combination of optical coherence tomography and elastography, to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology.
OncoRes was founded in 2016 and is based in Perth, Western Australia. OncoRes collaborates with leading researchers at the University of Western Australia, the Harry Perkins Institute of Medical Research and breast cancer surgeons and pathologists from the Western Australian Department of Health.
For more information please visit www.oncoresmedical.com

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
For more information please visit www.merck.com/index.html

Amgen is committed to the relentless pursuit of breakthroughs for cancer patients and their families. We are developing innovative medicines for novel targets in difficult-to-treat cancers. We are proud to be advancing the largest pipeline in our history in differentiated cancer therapies with the aim for large effect sizes. Our goal is to quickly bring new treatment options with the greatest potential benefit to patients.
For more information please visit www.amgen.com

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma is dedicated to advancing the treatment of HER2+ breast cancer and supporting women, their families and the breast cancer community.
For more information please visit www.pumabiotechnology.com

When life becomes life with cancer, it’s not only about fighting the disease. It’s a journey with ever-changing emotional and practical needs, not only for the person living with cancer, but also for everyone who’s part of the cancer journey—including the care team. That’s why we’re determined to do more than discover cancer medications. We’re committed to help meet those needs that go beyond treatment. Lilly Oncology makes more than medicine—we’re inspired to make a difference.
For more information please visit www.lillyoncology.com

Eisai gives first thought to patients and their families, and to increasing the benefits health care provides. Eisai is a human health care company capable of making a meaningful contribution under any health care system while observing the highest legal and ethical standards in business activities.
For more information please visit www.eisai.com